Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (21-30 of 188) with videos related to

Pageof 19
Sort By:
Cancer Journal (Sudbury, Mass.)|March 25, 2024
How Far We've ComeMario Sznol, Jeffrey S Weber
Seminars in Oncology|August 31, 2015
Cancer Immunotherapy: Past Progress and Future DirectionsMichael B Atkins, Mario Sznol
Journal for Immunotherapy of Cancer|March 26, 2015
Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplantMichael Cecchini, Mario Sznol, Stuart Seropian
Journal for Immunotherapy of Cancer|July 11, 2024
A crisis in clinical researchDavid S Hong, Patricia LoRusso, Mario Sznol
Oncology (Williston Park, N.Y.)|September 4, 2014
Advances in the systemic treatment of metastatic melanomaMelinda Yushak, Harriet M Kluger, Mario Sznol
Journal of Translational Medicine|April 22, 2010
Melanoma: a model for testing new agents in combination therapiesPaolo A Ascierto, Howard Z Streicher, Mario Sznol
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2019
Immunotherapy of Melanoma: Facts and HopesSarah A Weiss, Jedd D Wolchok, Mario Sznol
The Yale Journal of Biology and Medicine|December 20, 2011
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapyDallas B Flies, Britt J Sandler, Mario Sznol, et al.
Journal of Clinical Gastroenterology|May 2, 2013
Ipilimumab-induced perforating colitisKisha A Mitchell, Harriet Kluger, Mario Sznol, et al.
Seminars in Oncology|November 16, 2010
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodiesPaolo A Ascierto, Ester Simeone, Mario Sznol, et al.
Pageof 19

Showing results (21-30 of 188) with videos related to

Sort By:
Pageof 19
Cancer Journal (Sudbury, Mass.)|March 25, 2024
How Far We've ComeMario Sznol, Jeffrey S Weber
Seminars in Oncology|August 31, 2015
Cancer Immunotherapy: Past Progress and Future DirectionsMichael B Atkins, Mario Sznol
Journal for Immunotherapy of Cancer|March 26, 2015
Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplantMichael Cecchini, Mario Sznol, Stuart Seropian
Journal for Immunotherapy of Cancer|July 11, 2024
A crisis in clinical researchDavid S Hong, Patricia LoRusso, Mario Sznol
Oncology (Williston Park, N.Y.)|September 4, 2014
Advances in the systemic treatment of metastatic melanomaMelinda Yushak, Harriet M Kluger, Mario Sznol
Journal of Translational Medicine|April 22, 2010
Melanoma: a model for testing new agents in combination therapiesPaolo A Ascierto, Howard Z Streicher, Mario Sznol
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2019
Immunotherapy of Melanoma: Facts and HopesSarah A Weiss, Jedd D Wolchok, Mario Sznol
The Yale Journal of Biology and Medicine|December 20, 2011
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapyDallas B Flies, Britt J Sandler, Mario Sznol, et al.
Journal of Clinical Gastroenterology|May 2, 2013
Ipilimumab-induced perforating colitisKisha A Mitchell, Harriet Kluger, Mario Sznol, et al.
Seminars in Oncology|November 16, 2010
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodiesPaolo A Ascierto, Ester Simeone, Mario Sznol, et al.
Pageof 19